Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatmentChrysi Xintaropoulou, Simon P. Langdon|BMC Cancer|2018Cited by 107
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of<i>in vitro</i>breast cancer modelsCarol Ward, Simon P. Langdon|Oncotarget|2015Cited by 96
HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancerEdward J. Jarman, Simon P. Langdon|Breast Cancer Research|2019Cited by 69
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingPeter Mullen, Simon P. Langdon|Molecular Cancer Therapeutics|2007Cited by 55
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerAndrew H. Sims, Simon P. Langdon|British Journal of Cancer|2012Cited by 49